COCOMO-ACS Study: The Colchicine for coronary plaque modification in Acute Coronary Syndrome Study

This dataset includes 64 participants (median age 61.5 years; 9.4% female) with acute non-ST-segment elevation MI receiving colchicine 0.5 mg daily or placebo; in addition to guideline-recommended therapy. Participants underwent serial Optical Coherence Tomography (OCT) imaging within a matched segment of non-culprit coronary artery that contained at least one lipid-rich plaque causing ≥20% stenosis. At follow up (median of 17.8 months), the primary outcome was the change in minimum fibrous cap thickness (FCT) in non-culprit segments from baseline to final visit. The file is .PDF.